Bristol-Myers Squibb and China’s Hengrui Pharma Forge Tie-Up
RSS SUMMARY · AGGREGATED FROM TWSJ
U.S. pharma giant Bristol-Myers Squibb has struck a partnership and licensing deal with Chinese drugmaker Hengrui, in a deal that could worth more than $15 billion.
U.S. pharma giant Bristol-Myers Squibb has struck a partnership and licensing deal with Chinese drugmaker Hengrui, in a deal that could worth more than $15 billion.
U.S. pharma giant Bristol-Myers Squibb has struck a partnership and licensing deal with Chinese drugmaker Hengrui, in a deal that could worth more than $15 billion.
Continue Reading
The full story continues on The Wall Street Journal.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.
The Source
TWSJ
Business
Tencent Shareholder Prosus Hits Targets, Plans to Accelerate Investments in iFood
TWSJ·2h ago·3 min read
Business
Imperial Brands Revenue Rises, Fueled By Next-Generation Products
TWSJ·1h ago·3 min read
Business
EQT Makes Final $12.8 Billion Bid to Take Over Intertek
TWSJ·2h ago·3 min read
Business
Vodafone Swings to Pretax Profit on Revenue Growth
TWSJ·2h ago·3 min read
Related
On this beat
Health
Novo Nordisk Says Higher-Dose Wegovy Shot Helps Some Patients Lose 28% of Their Weight
TWSJ·2h ago·3 min read
Health
Americans enter quarantine after returning from hantavirus cruise ship
CBS NEWS·8h ago·3 min read
Health
NIH director on hantavirus risk
CBS NEWS·9h ago·3 min read
Health
Jim Cramer says today’s market is punishing stocks harder than 1999
CNBC·10h ago·3 min read